154 related articles for article (PubMed ID: 18029031)
1. Allosterism and cannabinoid CB(1) receptors: the shape of things to come.
Ross RA
Trends Pharmacol Sci; 2007 Nov; 28(11):567-72. PubMed ID: 18029031
[TBL] [Abstract][Full Text] [Related]
2. Tuning the endocannabinoid system: allosteric modulators of the CB1 receptor.
Ross RA
Br J Pharmacol; 2007 Nov; 152(5):565-6. PubMed ID: 17592508
[TBL] [Abstract][Full Text] [Related]
3. Binding thermodynamics at the human cannabinoid CB1 and CB2 receptors.
Merighi S; Simioni C; Gessi S; Varani K; Borea PA
Biochem Pharmacol; 2010 Feb; 79(3):471-7. PubMed ID: 19766600
[TBL] [Abstract][Full Text] [Related]
4. Novel sterically hindered cannabinoid CB1 receptor ligands.
Urbani P; Cascio MG; Ramunno A; Bisogno T; Saturnino C; Di Marzo V
Bioorg Med Chem; 2008 Aug; 16(15):7510-5. PubMed ID: 18579386
[TBL] [Abstract][Full Text] [Related]
5. Discovery of a novel class of selective human CB1 inverse agonists.
Foloppe N; Allen NH; Bentley CH; Brooks TD; Kennett G; Knight AR; Leonardi S; Misra A; Monck NJ; Sellwood DM
Bioorg Med Chem Lett; 2008 Feb; 18(3):1199-206. PubMed ID: 18083560
[TBL] [Abstract][Full Text] [Related]
6. 1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors.
Huffman JW; Padgett LW; Isherwood ML; Wiley JL; Martin BR
Bioorg Med Chem Lett; 2006 Oct; 16(20):5432-5. PubMed ID: 16889960
[TBL] [Abstract][Full Text] [Related]
7. 3D-QSAR studies on cannabinoid CB1 receptor agonists: G-protein activation as biological data.
Salo OM; Savinainen JR; Parkkari T; Nevalainen T; Lahtela-Kakkonen M; Gynther J; Laitinen JT; Järvinen T; Poso A
J Med Chem; 2006 Jan; 49(2):554-66. PubMed ID: 16420041
[TBL] [Abstract][Full Text] [Related]
8. Translational potential of allosteric modulators targeting the cannabinoid CB
Lu D; Immadi SS; Wu Z; Kendall DA
Acta Pharmacol Sin; 2019 Mar; 40(3):324-335. PubMed ID: 30333554
[TBL] [Abstract][Full Text] [Related]
9. Binding of orthosteric ligands to the allosteric site of the M(2) muscarinic cholinergic receptor.
Redka DS; Pisterzi LF; Wells JW
Mol Pharmacol; 2008 Sep; 74(3):834-43. PubMed ID: 18552124
[TBL] [Abstract][Full Text] [Related]
10. Substituted pyrimidines as cannabinoid CB1 receptor ligands.
Kim MJ; Kim JY; Seo HJ; Lee J; Lee SH; Kim MS; Kang J; Kim J; Lee J
Bioorg Med Chem Lett; 2009 Aug; 19(16):4692-7. PubMed ID: 19596576
[TBL] [Abstract][Full Text] [Related]
11. Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures--a short review.
Svízenská I; Dubový P; Sulcová A
Pharmacol Biochem Behav; 2008 Oct; 90(4):501-11. PubMed ID: 18584858
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and pharmacological evaluation of coumarin derivatives as cannabinoid receptor antagonists and inverse agonists.
Behrenswerth A; Volz N; Toräng J; Hinz S; Bräse S; Müller CE
Bioorg Med Chem; 2009 Apr; 17(7):2842-51. PubMed ID: 19278853
[TBL] [Abstract][Full Text] [Related]
13. Two-state models and the analysis of the allosteric effect of gallamine at the M2 muscarinic receptor.
Ehlert FJ; Griffin MT
J Pharmacol Exp Ther; 2008 Jun; 325(3):1039-60. PubMed ID: 18305010
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, cannabinoid receptor affinity, molecular modeling studies and in vivo pharmacological evaluation of new substituted 1-aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides. 2. Effect of the 3-carboxamide substituent on the affinity and selectivity profile.
Silvestri R; Ligresti A; La Regina G; Piscitelli F; Gatti V; Brizzi A; Pasquini S; Lavecchia A; Allarà M; Fantini N; Carai MA; Novellino E; Colombo G; Di Marzo V; Corelli F
Bioorg Med Chem; 2009 Aug; 17(15):5549-64. PubMed ID: 19595596
[TBL] [Abstract][Full Text] [Related]
15. Antagonistic cannabinoid CB1/dopamine D2 receptor interactions in striatal CB1/D2 heteromers. A combined neurochemical and behavioral analysis.
Marcellino D; Carriba P; Filip M; Borgkvist A; Frankowska M; Bellido I; Tanganelli S; Müller CE; Fisone G; Lluis C; Agnati LF; Franco R; Fuxe K
Neuropharmacology; 2008 Apr; 54(5):815-23. PubMed ID: 18262573
[TBL] [Abstract][Full Text] [Related]
16. Keynote review: Medicinal chemistry strategies to CB1 cannabinoid receptor antagonists.
Lange JH; Kruse CG
Drug Discov Today; 2005 May; 10(10):693-702. PubMed ID: 15896682
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and biological evaluation of piperazine analogues as CB1 cannabinoid receptor ligands.
Song KS; Lee SH; Chun HJ; Kim JY; Jung ME; Ahn K; Kim SU; Kim J; Lee J
Bioorg Med Chem; 2008 Apr; 16(7):4035-51. PubMed ID: 18243711
[TBL] [Abstract][Full Text] [Related]
18. Enantiospecific Allosteric Modulation of Cannabinoid 1 Receptor.
Laprairie RB; Kulkarni PM; Deschamps JR; Kelly MEM; Janero DR; Cascio MG; Stevenson LA; Pertwee RG; Kenakin TP; Denovan-Wright EM; Thakur GA
ACS Chem Neurosci; 2017 Jun; 8(6):1188-1203. PubMed ID: 28103441
[TBL] [Abstract][Full Text] [Related]
19. Allosteric enhancers, allosteric agonists and ago-allosteric modulators: where do they bind and how do they act?
Schwartz TW; Holst B
Trends Pharmacol Sci; 2007 Aug; 28(8):366-73. PubMed ID: 17629958
[TBL] [Abstract][Full Text] [Related]
20. Characterization of a cannabinoid CB2 receptor-selective agonist, A-836339 [2,2,3,3-tetramethyl-cyclopropanecarboxylic acid [3-(2-methoxy-ethyl)-4,5-dimethyl-3H-thiazol-(2Z)-ylidene]-amide], using in vitro pharmacological assays, in vivo pain models, and pharmacological magnetic resonance imaging.
Yao BB; Hsieh G; Daza AV; Fan Y; Grayson GK; Garrison TR; El Kouhen O; Hooker BA; Pai M; Wensink EJ; Salyers AK; Chandran P; Zhu CZ; Zhong C; Ryther K; Gallagher ME; Chin CL; Tovcimak AE; Hradil VP; Fox GB; Dart MJ; Honore P; Meyer MD
J Pharmacol Exp Ther; 2009 Jan; 328(1):141-51. PubMed ID: 18931146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
